Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (2989)	8/29/2011 3:05:26 PM
From: Jibacoa	Respond to of 3722

BCRX is up 15,48% on volume of 314Ks, which is already above its ADV. bigcharts.marketwatch.com BCRX designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It has three compounds in late stage development: Peramivir, a neuraminidase inhibitor for the potential treatment of influenza. BCX4208, a purine nucleoside phosphorylase inhibitor for gout. Forodesine, a PNP inhibitor for cutaneous T-cell lymphoma and chronic lymphocytic leukemia. BCRX reported a net loss of $16.3M for the Q2 that ended June 30 vs a loss of $10.2M in 2010. That was about $0.36 vs. the expected $0.25.<g> Revenues fell to $3.7M from $7.6M as government funding decreased because Piramivir's clinical trials reportedly are complete.<g> The ACTAY is $6.50 But the insiders and institutions had been heavy sellers until recently. <g>bigcharts.marketwatch.com Bernard